This article was originally published on 12 April 2008 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.
The MRSA burden and the vaccine imperative
Methicillin-resistant Staphylococcus aureus (MRSA) had by 2008 become one of the defining public health crises of the developed world's healthcare systems. In the United States alone, the CDC estimated that MRSA caused approximately 94,000 serious infections and nearly 19,000 deaths annually - a mortality burden exceeding that of HIV/AIDS in the same period. In European hospitals, MRSA bloodstream infection rates varied widely by country but represented a major driver of antibiotic resistance and healthcare costs across all systems.
Estimated annual US deaths from MRSA infections in 2007 - exceeding HIV/AIDS mortality and establishing the clear public health imperative for a prophylactic vaccine
Why prior attempts failed
The history of Staph vaccine development was characterised by promising early-phase data followed by late-stage clinical failures. StaphVAX (Nabi Biopharmaceuticals), a capsular polysaccharide conjugate targeting serotypes 5 and 8, had failed in a Phase III trial in haemodialysis patients despite strong Phase II immunogenicity. V710 (Merck, based on the IsdB iron surface protein) was at an advanced stage but would subsequently also fail in Phase III. The pattern of immunogenicity without clinical efficacy was beginning to point to fundamental uncertainties about the correlates of protection for S. aureus.
"The Staph vaccine graveyard reflects a fundamental challenge: we do not yet know what immune response is required to protect against S. aureus - and until we do, even well-designed vaccines remain shots in the dark."